Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium
- Aadi Bioscience will present a phase 2 study of nab-sirolimus in patients with well-differentiated and advanced or metastatic neuroendocrine tumors
- The study will evaluate the efficacy and safety of nab-sirolimus in up to 21 patients
- Enrollment for the study is planned to begin in the third quarter of 2023
- None.
Details of the poster presentations are below:
Title: "Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced or metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas"
Date/Time: Thursday, October 5, 2023, 5:15 pm – 7:00 pm EDT
Presentation Location: Poster Gallery Location, Square Dorchester
Presenter: Scott Paulson, MD
Authors: Michael J. Demeure, MD; Allen L. Cohn, MD; Tara Seery, MD; Li Ding, MS, MA; Usman Aziz, MD; Willis Navarro, MD; Scott Paulson, MD
Highlights:
- The PI3K/AKT/mTOR pathway has been implicated in the pathogenesis and progression of NETs, though the use of oral mTORis as a treatment for NETs is limited by low bioavailability and the heterogeneity of the disease
- nab-Sirolimus is a nanoparticle albumin-bound mTORi designed to preferentially target tumors and overcome the limitations of oral sirolimus
- nab-Sirolimus is currently approved in
the United States for the treatment of malignant perivascular epithelioid cell neoplasms - The efficacy and safety of nab-sirolimus in patients with advanced or metastatic NETs will be evaluated in this phase 2, multicenter, open-label, single-arm, US-based study
- The study, NET-202 (NCT05997056), will enroll up to 21 efficacy evaluable patients at approximately three US centers. Enrollment for the study is planned to begin in the third quarter of 2023, with completion expected within 12–18 months
An encore presentation titled, "Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)" will also be presented on Thursday, October 5, 2023.
More information can be found on the North American Neuroendocrine Tumor Society (NANETS) website.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval in November 2021, and in February 2022 commenced commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Aadi is conducting the PRECISION1 trial, a Phase 2 tumor-agnostic registration-directed study in patients with mTOR inhibitor-naïve malignant solid tumors harboring TSC1/TSC2 inactivating alterations. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Contact:
Marcy Graham
IR@aadibio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-announces-poster-presentations-at-the-north-american-neuroendocrine-tumor-society-nanets-2023-multidisciplinary-net-medical-symposium-301948926.html
SOURCE Aadi Bioscience
FAQ
What is Aadi Bioscience presenting at the NANETS Medical Symposium?
How many patients will be enrolled in the study?
When will enrollment for the study begin?
